Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 9,907 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Arm Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Hip Activation and FSDT

NCT05642065
View directory record Official record
Conditions
Movement, Abnormal, Lower Extremity Problem
Interventions
Hip muscle activation home exercise program
Other
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 25, 2026, 7:26 PM EDT
Recruiting Phase 1Phase 2 Interventional

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07190300
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Tulmimetostat, Darolutamide, Abiraterone, Prednisone/Prednisolone, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Results available

Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy

NCT00535392
View directory record Official record
Conditions
Epilepsy
Interventions
Levetiracetam
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
4 Years to 16 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
La Jolla, California • Boston, Massachusetts • Chesterfield, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Oct 25, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction

NCT00433771
View directory record Official record
Conditions
Cholestasis, Extrahepatic
Interventions
WallFlex™ Biliary Fully Covered Metal Stent placement
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
San Francisco, California • Aurora, Colorado • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2010 · Synced Oct 25, 2026, 7:26 PM EDT
Completed Not applicable Interventional

SERF VT Ablation Early Feasibility Study (EFS)

NCT03628534
View directory record Official record
Conditions
Ventricular Tachycardia, Arrythmia, Heart Diseases, Cardiovascular Diseases
Interventions
Saline Enhanced Radiofrequency (SERF) ablation
Device
Lead sponsor
Thermedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Maywood, Illinois • Rochester, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 25, 2026, 7:26 PM EDT
Recruiting Phase 2 Interventional

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

NCT04253964
View directory record Official record
Conditions
Nonsmall Cell Lung Cancer, Performance Status
Interventions
Pembrolizumab, Atezolizumab, Cemiplimab-Rwlc, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed, Cisplatin, Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13), QLQ-C30 Global Health/Quality of Life Questionnaire, COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes, PROMIS and FACT-G Questionnaires, Sleep Disorder Assessments (ISI, Berlin Sleep Questionnaire)
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 7:26 PM EDT
Completed Not applicable Interventional

Rehab CARES In USA: Clinical Trial

NCT05542121
View directory record Official record
Conditions
Stroke, Hemiplegia
Interventions
Robot-Assisted Therapy with Rehab CARES system, Standard of Care
Device · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 25, 2026, 7:26 PM EDT
Completed Not applicable Interventional

Double Arm Pivotal Study to Evaluate the Neurolyser XR for the Treatment of Chronic Low Back Pain

NCT05154448
View directory record Official record
Conditions
Facet Syndrome of Lumbar Spine
Interventions
Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR), Sham procedure
Device · Other
Lead sponsor
FUSMobile Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Stamford, Connecticut • Jacksonville, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 25, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

NCT00230178
View directory record Official record
Conditions
Tumor Lysis Syndrome, Cancer, Hyperuricemia
Interventions
Rasburicase (SR29142), Allopurinol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
15
States / cities
Berkeley, California • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Oct 25, 2026, 7:26 PM EDT
Completed Not applicable Interventional

Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes

NCT02914743
View directory record Official record
Conditions
Type II Diabetes, Periodontal Disease
Interventions
Motivational Interviewing, Dental cleaning
Behavioral · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 25, 2026, 7:26 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Skin Elasticity Measurements of the Face and Surgical Scars Stratified by Age and Skin Type

NCT01688063
View directory record Official record
Conditions
Skin Scarring, Skin Elasticity
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 25, 2026, 7:26 PM EDT
Terminated Not applicable Interventional

Mindfulness Oriented Recovery Enhancement in Hospitalized People With Opioid Use Disorder

NCT05066321
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Mindfulness Oriented Recovery Enhancement Sessions
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 25, 2026, 7:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating the Availability of Berry Phytonutrients Post-consumption of Fresh and Processed Blueberry by Healthy Adults

NCT04175106
View directory record Official record
Conditions
Healthy
Interventions
a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value, a standard commercially available blueberry variety (i.e., cultivar), a "minimally processed" blueberry-rich protein bar, a control beverage of matched-nutritive content
Other
Lead sponsor
North Carolina State University
Other
Eligibility
25 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 25, 2026, 7:26 PM EDT
Not yet recruiting Phase 4 Interventional

Assessing the Efficacy of Indocyanine Green for Ureter Identification During Robot-Assisted Surgery in Advanced-Stage Endometriosis

NCT07144904
View directory record Official record
Conditions
Indocyanine Green (ICG), Robotic Surgical Procedure, Deep Infiltrating Endometriosis (DIE), Endometriosis Pelvic, Endometriosis (Diagnosis), Endometriosis of the Cul-de-sac, Ureteral Stent Placement, Ureteral Injury, Endometriosis Ovaries
Interventions
Indocyanine Green (ICG)-Assisted Ureteral Identification, Standard Ureteral Identification without ICG
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 25, 2026, 7:26 PM EDT
Terminated Phase 4 Interventional Results available

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

NCT04626947
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, C. Diff. Infections
Interventions
Bezlotoxumab
Biological
Lead sponsor
David Binion, MD
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 25, 2026, 7:26 PM EDT
Completed Phase 1 Interventional

Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

NCT00334438
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, yttrium Y 90 ibritumomab tiuxetan, Indium 111 ibritumomab tiuxetan
Biological · Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Hackensack, New Jersey • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 25, 2026, 7:26 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Pharmacogenomic Modulators of Impaired Exercise Adaptation in Statin Users

NCT04636138
View directory record Official record
Conditions
HMG-CoA Reductase Inhibitor Toxicity
Interventions
Exercise
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 25, 2026, 7:26 PM EDT
Terminated Phase 2 Interventional Results available

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

NCT01995058
View directory record Official record
Conditions
Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms
Interventions
cabozantinib, abiraterone, prednisone
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
20
States / cities
Scottsdale, Arizona • Sedona, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 25, 2026, 7:26 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 25, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept

NCT01901185
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis
Interventions
Etanercept / Autoinjector A
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 25, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

NCT03367715
View directory record Official record
Conditions
MGMT-unmethylated Glioblastoma (GBM), GBM
Interventions
Nivolumab, Ipilimumab, Radiation Therapy (RT)
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 25, 2026, 7:26 PM EDT
Completed No phase listed Observational

WeighT LOSS Surgery and Comprehensive Cardiometabolic Responses to to EXercise

NCT06576050
View directory record Official record
Conditions
Heart Failure, Obesity, Weight Loss, Heart Failure With Preserved Ejection Fraction
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 25, 2026, 7:26 PM EDT
Withdrawn Phase 2 Interventional

Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

NCT01882374
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
TXA127
Drug
Lead sponsor
Tarix Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 25, 2026, 7:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Two Different Tablet Formulations Of Bosutinib

NCT00934674
View directory record Official record
Conditions
Healthy
Interventions
SKI-606 (Bosutinib)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Oct 25, 2026, 7:26 PM EDT